Sahlgrenska Science Park’s Post

𝐁𝐈𝐎-𝐎𝐒𝐂𝐀𝐑 𝐒𝐎𝐂 𝐒𝐓𝐔𝐃𝐘 : A prospective, multicenter, observational study evaluating standard of care practices, procedural outcomes, and in-hospital complications of endovascular procedures for treatment of atherosclerotic lesions in the infrainguinal arteries. 🔄 Update on the status of the BIO-OSCAR SOC study as of October 4th 👉  32 subjects enrolled with 8 sites open for enrolment 🎯 To reach the target, 2 patients per week need to be enrolled at each site! Hôpital Paris Saint-Joseph BIOTRONIK #biooscarstudy #biooscarsoc #observationalstudy #endovascular #treatment #atherosclerotic #atheroscleroticlesions #infrainguinalarteries #clinicalstrial #groupehospitalierparissaintjoseph #hopitalparissaintjoseph #biotronik

𝐁𝐈𝐎-𝐎𝐒𝐂𝐀𝐑 𝐒𝐎𝐂 𝐒𝐓𝐔𝐃𝐘 : A prospective, multicenter, observational study evaluating standard of care practices, procedural outcomes, and in-hospital complications of endovascular procedures for treatment of atherosclerotic lesions in the infrainguinal arteries. 🔄 Update on the status of the BIO-OSCAR SOC study as of November 24th 👉 𝟕𝟓 𝐬𝐮𝐛𝐣𝐞𝐜𝐭𝐬 𝐞𝐧𝐫𝐨𝐥𝐥𝐞𝐝 𝐰𝐢𝐭𝐡 𝟏𝟎 𝐬𝐢𝐭𝐞𝐬 𝐨𝐩𝐞𝐧 𝐟𝐨𝐫 𝐞𝐧𝐫𝐨𝐥𝐦𝐞𝐧𝐭 Hôpital Paris Saint-Joseph BIOTRONIK #biooscarstudy #biooscarsoc #observationalstudy #endovascular #treatment #atherosclerotic #atheroscleroticlesions #infrainguinalarteries #clinicalstrial #groupehospitalierparissaintjoseph #hopitalparissaintjoseph #biotronik

𝐁𝐈𝐎-𝐎𝐒𝐂𝐀𝐑 𝐒𝐎𝐂 𝐒𝐓𝐔𝐃𝐘 : A prospective, multicenter, observational study evaluating standard of care practices, procedural outcomes, and in-hospital complications of endovascular procedures for treatment of atherosclerotic lesions in the infrainguinal arteries. 🔄 Update on the status of the BIO-OSCAR SOC study as of December 5th 👉 𝟗𝟏 𝐬𝐮𝐛𝐣𝐞𝐜𝐭𝐬 𝐞𝐧𝐫𝐨𝐥𝐥𝐞𝐝 𝐰𝐢𝐭𝐡 𝟏𝟏 𝐬𝐢𝐭𝐞𝐬 𝐨𝐩𝐞𝐧 𝐟𝐨𝐫 𝐞𝐧𝐫𝐨𝐥𝐦𝐞𝐧𝐭 Hôpital Paris Saint-Joseph BIOTRONIK #biooscarstudy #biooscarsoc #observationalstudy #endovascular #treatment #atherosclerotic #atheroscleroticlesions #infrainguinalarteries #clinicalstrial #groupehospitalierparissaintjoseph #hopitalparissaintjoseph #biotronik

𝐁𝐈𝐎-𝐎𝐒𝐂𝐀𝐑 𝐒𝐎𝐂 𝐒𝐓𝐔𝐃𝐘 : A prospective, multicenter, observational study evaluating standard of care practices, procedural outcomes, and in-hospital complications of endovascular procedures for treatment of atherosclerotic lesions in the infrainguinal arteries. 🔄 Update on the status of the BIO-OSCAR SOC study 👉 𝟏𝟎𝟗 𝐬𝐮𝐛𝐣𝐞𝐜𝐭𝐬 𝐞𝐧𝐫𝐨𝐥𝐥𝐞𝐝 𝐰𝐢𝐭𝐡 𝟏𝟐 𝐬𝐢𝐭𝐞𝐬 𝐨𝐩𝐞𝐧 𝐟𝐨𝐫 𝐞𝐧𝐫𝐨𝐥𝐦𝐞𝐧𝐭 Hôpital Paris Saint-Joseph BIOTRONIK #biooscarstudy #biooscarsoc #observationalstudy #endovascular #treatment #atherosclerotic #atheroscleroticlesions #infrainguinalarteries #clinicalstrial #groupehospitalierparissaintjoseph #hopitalparissaintjoseph #biotronik

Give the below a read from Kendra J. Grubb, MD, MHA, FACC ⬇️

Every three seconds, someone in the world is impacted by a stroke, and the World Stroke Organization reports that 101 million people are living with its consequences. May is #NationalStrokeAwarenessMonth and we at Siemens Healthineers are deeply committed to the fight against this global health challenge. We invite you to explore our integrated stroke solutions, see how we streamline stroke workflows to address potential challenges. Join us on this journey to shape the future of stroke care. Together, we can make a significant difference. For effective stroke treatment and positive patient outcomes, every second counts. Healthcare professionals are dedicated to establishing the fastest possible diagnosis and treatment pathways for their patients. A seamless treatment journey is critical for delivering optimal care and for preventing further incidents. Our imaging technologies play a pivotal role in a variety of stroke scenarios, helping to identify conditions. Moreover, our ARTIS icono is instrumental in supporting the continuum of care with endovascular treatments. 🎥 Watch our informative video now! https://lnkd.in/emhqMtv7 #StrokeCare #HealthcareInnovation #SiemensHealthineers 

CTS Retina, what an incredible conference, that brought together leaders in industry, financial investment, and clinical research. Probably the most I have learned at a conference in a single day ever! I must congratulate founder Dr. Arshad M. Khanani, and his co-chairs, Dr. Jeff Heier and Dr. Peter Kaiser, for such a thoughtful and engaging agenda.  Some of the key things I learned: 1. There is 𝗴𝗿𝗼𝘄𝗶𝗻𝗴 𝗵𝗼𝗽𝗲 𝘁𝗵𝗮𝘁 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀 𝘄𝗶𝘁𝗵 𝗚𝗲𝗼𝗴𝗿𝗮𝗽𝗵𝗶𝗰 𝗔𝘁𝗿𝗼𝗽𝗵𝘆, an advanced form of macular degeneration that impacts millions around the world, can potentially see benefits in functional outcomes. This requires novel approaches towards assessing visual function. 2. The adherence of patients with diabetic complications remains a challenge and multiple 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁𝘀 𝗶𝗻 𝘁𝗵𝗲 𝗳𝗼𝗿𝗺 𝗼𝗳 𝗲𝘆𝗲 𝗱𝗿𝗼𝗽𝘀 𝗮𝗻𝗱 𝗼𝗿𝗮𝗹 𝗺𝗲𝗱𝗶𝗰𝗮𝘁𝗶𝗼𝗻 that under investigation provide a potential solution. 3. 𝗗𝗶𝗴𝗶𝘁𝗮𝗹 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 𝗵𝗮𝘀 𝗮𝗿𝗿𝗶𝘃𝗲𝗱 𝘁𝗼 𝘁𝗵𝗲 𝗿𝗲𝘁𝗶𝗻𝗮𝗹 𝗰𝗮𝗿𝗲 𝘄𝗶𝘁𝗵 𝘁𝗵𝗲 𝗮𝗽𝗽𝗿𝗼𝘃𝗮𝗹 𝗼𝗳 𝗵𝗼𝗺𝗲 𝗢𝗖𝗧, Dr. Christina Weng, protocol chair for a randomized control using home OCT shared positive experience with the technology. Dr Jeff Heier, presented results from a prospective home study, showing impact on patient management. Dr. Heier also received the 1st Prof. Ramin Tadayoni “Summit of Excellence” Award! 4. The importance of independent real world studies. Dr. David Eichenbaum presented the first ever real world study on real world outcomes using Aflibercept 8-mg and Dr. David RP Almeida MD MBA PhD presented, promising real world outcomes of Faricimab. #innovation #clinicaltrials

𝐁𝐈𝐎-𝐎𝐒𝐂𝐀𝐑 𝐒𝐎𝐂 𝐒𝐓𝐔𝐃𝐘 : A prospective, multicenter, observational study evaluating standard of care practices, procedural outcomes, and in-hospital complications of endovascular procedures for treatment of atherosclerotic lesions in the infrainguinal arteries. 🔄 Update on the status of the BIO-OSCAR SOC study 👉 𝟏𝟔𝟐 𝐬𝐮𝐛𝐣𝐞𝐜𝐭𝐬 𝐞𝐧𝐫𝐨𝐥𝐥𝐞𝐝 𝐰𝐢𝐭𝐡 𝟏𝟐 𝐬𝐢𝐭𝐞𝐬 𝐨𝐩𝐞𝐧 𝐟𝐨𝐫 𝐞𝐧𝐫𝐨𝐥𝐦𝐞𝐧𝐭 Hôpitaux Saint-Joseph & Marie-Lannelongue BIOTRONIK #biooscarstudy #biooscarsoc #observationalstudy #endovascular #treatment #atherosclerotic #atheroscleroticlesions #infrainguinalarteries #clinicalstrial #groupehospitalierparissaintjoseph #hopitalparissaintjoseph #biotronik

New insights from a prospective study on Glanzmann thrombasthenia (GT) have been published in Blood (2023). Led by Catherine Rea, Dr Tom York, Ulrike Lorch, and their team, this observational study delves into the bleeding patterns and impacts on quality of life (QOL) in 30 GT patients over 3 months. Using a custom-designed electronic bleed diary, the study reveals the high frequency of bleeds and their substantial socioeconomic impacts. Results detail bleed rates, anatomical locations, associated symptoms, and the burden on daily activities. The findings underscore the urgent need for improved treatments to reduce bleed frequency and enhance QOL for GT patients. This study establishes a direct correlation between bleed events and their profound effects on patients' lives, advocating for advancements in GT care. Read more: https://ow.ly/JvUS50QhYrN #GlanzmannThrombasthenia #MedicalResearch #BloodJournal #QualityOfLife #ResearchInsights"

Every three seconds, someone somewhere in the world is affected by a stroke, and according to the World Stroke Organization, 101 million people are living with the aftermath of a stroke. For an optimized stroke treatment and a good patient outcome, time is of the essence. Healthcare practitioners aim to set up the ideal pathway for fast diagnosis and treatment of their patients. A well-coordinated treatment pathway is essential for optimal care and prevention to reduce the recurrence rate. Imaging technologies assist in a wide range of stroke scenarios identifying conditions such as blood clots, carotid plaques or a vessel ruptures, while our ARTIS icono therapy device plays a key role in supporting the continuum of care through endovascular treatment. Explore our integrated stroke solutions to see how to streamline a stroke workflow to overcome possible constraints. 🎥 Watch our informative video now! https://lnkd.in/d7vFhSBJ #StrokeCare #HealthcareInnovation #SiemensHealthineers